Myeloma Center

Bibliography

Found 45 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is G  [Clear All Filters]
2010
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
2011
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA.  2011.  Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.. Cancer. 117(2):336-42.
2012
A Wernicke G, Sabbas A, Kulidzhanov F, Shamis M, Golster Y, Niesvizky R, Lane J.  2012.  A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.. HSS J. 8(2):169-74.
2013
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T.  2013.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T.  2013.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.
Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.  2013.  Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. Br J Haematol. 163(4):478-86.
2014
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J et al..  2014.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.. Blood. 124(7):1047-55.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..  2014.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.
2015
A Stewart K, S Rajkumar V, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Mihaylov GG et al..  2015.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.. N Engl J Med. 372(2):142-52.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al..  2015.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al..  2015.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.
2016
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosiñol L, Goranova-Marinova V, Mihaylov G et al..  2016.  Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.. Blood. 128(9):1174-80.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
2017
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al..  2017.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.